CULTA

Executive Summary

CULTA is a Japanese biotechnology company specializing in advanced cell and gene therapies for oncology. Founded in 2018 and based in Tokyo, the company is developing both ex vivo and in vivo approaches to engineer immune cells for more potent and accessible cancer treatments. Its platform technology targets difficult-to-treat malignancies, leveraging innovations in gene editing and cell engineering. Despite being in the platform stage, CULTA has not disclosed significant funding rounds or valuation, but its focus on next-generation cell therapies positions it within a competitive but high-growth sector. The company's success hinges on preclinical and early clinical validation of its proprietary platforms, which could address key limitations of current CAR-T and gene therapy modalities, such as manufacturing complexity and solid tumor efficacy.

Upcoming Catalysts (preview)

• Q3 2026First-in-human clinical trial initiation for lead ex vivo cell therapy candidate30% success
• Q4 2026Partnership or licensing deal with a larger pharmaceutical company for in vivo gene therapy platform40% success
• Q2 2026Presentation of preclinical proof-of-concept data at a major oncology conference (e.g., ASCO or ESMO)60% success